Patrick O'Brien | Investor Relations |
John Higgins | Chief Executive Officer |
Matt Korenberg | Executive Vice President, Finance & Chief Financial Officer |
Matt Foehr | President & Chief Operating Officer |
Matt Hewitt | Craig-Hallum Capital Group |
Joe Pantginis | H.C. Wainwright |
Balaji Prasad | Barclays |
Larry Solow | CJS Securities |
Scott Henry | Roth Capital |
Ladies and gentlemen, thank you for standing by and welcome to the Ligand Pharmaceuticals Q2 2020 Earnings Conference Call. At this time all participants’ lines are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions]. I would now like to hand the conference over to Patrick O'Brien, SVP of Investor Relations.